Nathalie Chauret
Corporate Officer/Principal at BELLUS HEALTH
Profile
Nathalie Chauret is currently working as a Director at Gladius Pharmaceuticals, Inc. and Gladius Pharmaceuticals Corp.
She is also currently serving as the Vice President-Early Phase Development at BELLUS Health, Inc. In terms of education, Ms. Chauret has a graduate degree from the University of Montréal.
Nathalie Chauret active positions
Companies | Position | Start |
---|---|---|
BELLUS HEALTH | Corporate Officer/Principal | 01/01/2017 |
Gladius Pharmaceuticals, Inc.
Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Director/Board Member | - |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Director/Board Member | - |
Training of Nathalie Chauret
University of Montréal | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Gladius Pharmaceuticals, Inc.
Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Health Technology |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Health Technology |
BELLUS Health, Inc.
BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Stock Market
- Insiders
- Nathalie Chauret